In the last 2 decades, BTX-A is increasingly being used in the management of spasticity in children with Cerebral Palsy (CP) and there is no doubt about its effect on range of motion, spasticity reduction and gait pattern in this patient population. However, in daily practice, there is still an ongoing search for the best way to apply BTX-A. Two studies were set up to evaluate how successful an integrated multilevel treatment approach is in children with CP. The first study identifies crucial factors within the treatment strategy which may predict the outcome. The second study evaluates the efficacy of repeated BTX-A injections.status: publishe
WOS: 000187502500005PubMed ID: 14643391The current modalities in managing spastic children have some...
WOS: 000187502500005PubMed ID: 14643391The current modalities in managing spastic children have some...
Background: Botulinum toxin A (BTX-A) has been used to reduce spasticity in children with cerebral p...
In the last 2 decades, BTX-A is increasingly being used in the management of spasticity in children ...
Botulinum toxin A (BTA) inhibits presynaptic release of acetylcholine at the neuromuscular junction ...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-A) in t...
A systematic review with the Sachett model of evidence-based medicine of the use of Botulinum toxin ...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Botulinum toxin type A (BTX-A) is increasingly bring used for the treatment of childhood spasticity,...
This study evaluated the effects of multilevel botulinum toxin type A (BTX-A) treatments on the gait...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
We prospectively studied the medium-term effects of botulinum toxin type A (BTX-A) treatment in 197 ...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
It is recognized that objective gait analysis is of great value in planning a multilevel botulinum t...
WOS: 000187502500005PubMed ID: 14643391The current modalities in managing spastic children have some...
WOS: 000187502500005PubMed ID: 14643391The current modalities in managing spastic children have some...
Background: Botulinum toxin A (BTX-A) has been used to reduce spasticity in children with cerebral p...
In the last 2 decades, BTX-A is increasingly being used in the management of spasticity in children ...
Botulinum toxin A (BTA) inhibits presynaptic release of acetylcholine at the neuromuscular junction ...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-A) in t...
A systematic review with the Sachett model of evidence-based medicine of the use of Botulinum toxin ...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Botulinum toxin type A (BTX-A) is increasingly bring used for the treatment of childhood spasticity,...
This study evaluated the effects of multilevel botulinum toxin type A (BTX-A) treatments on the gait...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
We prospectively studied the medium-term effects of botulinum toxin type A (BTX-A) treatment in 197 ...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
It is recognized that objective gait analysis is of great value in planning a multilevel botulinum t...
WOS: 000187502500005PubMed ID: 14643391The current modalities in managing spastic children have some...
WOS: 000187502500005PubMed ID: 14643391The current modalities in managing spastic children have some...
Background: Botulinum toxin A (BTX-A) has been used to reduce spasticity in children with cerebral p...